|
Getting your Trinity Audio player ready...
|
Two full doses of the Corona vaccine (CoveShield) of Oxford University and AstraZeneca Company give a better immune response. Oxford University gave this information on Thursday night. The university said in a statement “Earlier we tried by giving a full and a half dose. That is, the candidate was given one and a half doses. Now two full doses were given. Their results were much better.”
About a month ago, AstraZeneca and Oxford admitted to manufacturing errors in the vaccine. The results of the third phase trial of the vaccine were then released, with varying results.
Only two full doses are necessary
In a statement released on Thursday, Oxford gave new information on its vaccine. Said- We gave our candidates two full doses of vaccine during the trial. This led to good results. Earlier we had given a whole and a half dose. In comparison, two full doses proved to be very effective.
The latest statement of the company has come at a time when in the past itself it had agreed to different results. Experts had then questioned its data analysis as well. In a new statement, Oxford has acknowledged that more work needs to be done to confirm the vaccine results.
Three-phase details released
Oxford released the trial results of Phase 1 to Phase 3 for the second time in a month. However, the reference to the first one and the half dose was not given in it. The university says that the trials to be given one and a half doses were not pre-decided. Now Oxford’s emphasis is only on giving two full doses of its vaccine. He says that using one and a half and two doses were part of his strategy. Earlier questions have been raised on this because the difference in results is also natural due to difference in dosage.
Oxford said that the results that were given after the booster dose showed that antibodies are made faster than single doses. Standard doses should only be used.
The question was raised earlier
Oxford / AstraZeneca released a statement on 23 November stating that the vaccine (AZD1222) was found to be highly effective in tests conducted in the UK and Brazil. The vaccine was found to be up to 90% effective at half dose. After this, 62% was seen effective when given full dose in the second month. A month later, the effect of the vaccine was observed to be 70% when given two full doses. In India, this vaccine is being developed by the Serum Institute of India, Pune.